Insurance Coverage: Is cabozantinib covered by the latest medical insurance?

Cabozantinib (Cabozantinib) is a targeted therapy drug that belongs to the category of multi-target tyrosine kinase inhibitors. It is designed to treat several types of cancer, including advanced renal cell carcinoma, thyroid cancer, and hepatocellular carcinoma.

Because cabozantinib has not yet obtained marketing approval in China, domestic patients cannot purchase this drug directly from pharmacies or hospitals. However, there are opportunities to obtain cabozantinib through foreign channels, including original drugs and generic drugs. Original drugs, that is, drugs originally developed, are usually expensive. For example, in Japan and Europe, the price may be as high as 30,000 to 40,000 yuan. In comparison, the price of generic drugs appears to be more affordable. For example, generic drugs from Laos, India, Bangladesh and other places are sold for only a few hundred to several thousand yuan, providing more choices for patients with limited financial conditions. It needs to be emphasized that the main drug ingredients of these original drugs and generic drugs are basically the same. Therefore, when choosing, patients can make the decision that best suits them based on their own financial situation and disease needs.

As a targeted therapy drug, cabozantinib’s mechanism of action is mainly by inhibiting multiple key signaling pathways, thereby inhibiting the growth, spread and angiogenesis of cancer cells. Cabozantinib mainly acts on multiple receptor tyrosine kinases (RTKs), including MET (hepatocyte growth factor receptor), VEGFR (vascular endothelial growth factor receptor) , RET (rearranged oncogene family receptor kinase), KIT (cytoplasmic tyrosine kinase) and AXL (axon-associated protein kinase), etc. By inhibiting the activity of these receptor tyrosine kinases, cabozantinib can effectively block the growth signaling of tumor cells, thereby inhibiting the growth and metastasis of tumor cells.

In addition, cabozantinib can also inhibit the vascular endothelial growth factor (VEGF) signaling pathway, thereby inhibiting the formation of new blood vessels in tumors, reducing the blood supply to tumors, and thereby inhibiting tumor growth and metastasis.

Cabozantinib is often used as a single agent or in combination with other treatments, such as immunotherapy or chemotherapy, to treat patients with advanced cancer. Its dosage and treatment regimen may vary depending on the patient's condition and doctor's recommendations.